S&P 500   3,088.92 (-0.09%)
DOW   27,680.64 (-0.04%)
QQQ   201.39 (-0.07%)
CGC   18.63 (-3.22%)
BABA   184.13 (-1.52%)
GE   11.27 (-1.31%)
F   8.93 (-1.22%)
ACB   3.52 (-1.40%)
PRI   128.06 (-1.45%)
DIS   137.69 (-0.64%)
S&P 500   3,088.92 (-0.09%)
DOW   27,680.64 (-0.04%)
QQQ   201.39 (-0.07%)
CGC   18.63 (-3.22%)
BABA   184.13 (-1.52%)
GE   11.27 (-1.31%)
F   8.93 (-1.22%)
ACB   3.52 (-1.40%)
PRI   128.06 (-1.45%)
DIS   137.69 (-0.64%)
Log in

Ekso Bionics Stock Price, Forecast & Analysis (NASDAQ:EKSO)

$0.62
-0.01 (-1.59 %)
(As of 11/13/2019 10:29 AM ET)
Today's Range
$0.61
Now: $0.62
$0.62
50-Day Range
$0.49
MA: $0.58
$0.69
52-Week Range
$0.48
Now: $0.62
$2.55
Volume500 shs
Average Volume445,338 shs
Market Capitalization$46.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. Read More…

Industry, Sector and Symbol

Industry General industrial machinery,
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EKSO
Previous SymbolOTCMKTS:EKSOD
CUSIPN/A
Phone510-984-1761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.33 million
Book Value$0.04 per share

Profitability

Net Income$-26,990,000.00
Net Margins-100.36%

Miscellaneous

Employees77
Market Cap$46.47 million
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable

Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.


Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Ekso Bionics shares reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings Inc (NASDAQ:EKSO) issued its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $3.32 million for the quarter. Ekso Bionics had a negative net margin of 100.36% and a negative return on equity of 376.63%. View Ekso Bionics' Earnings History.

When is Ekso Bionics' next earnings date?

Ekso Bionics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Ekso Bionics.

What price target have analysts set for EKSO?

3 brokers have issued twelve-month target prices for Ekso Bionics' shares. Their forecasts range from $1.00 to $2.90. On average, they expect Ekso Bionics' share price to reach $1.70 in the next year. This suggests a possible upside of 174.2% from the stock's current price. View Analyst Price Targets for Ekso Bionics.

What is the consensus analysts' recommendation for Ekso Bionics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ekso Bionics.

What are Wall Street analysts saying about Ekso Bionics stock?

Here are some recent quotes from research analysts about Ekso Bionics stock:
  • 1. According to Zacks Investment Research, "Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company's operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. " (11/6/2019)
  • 2. Aegis analysts commented, "We think conversion rate is an interesting metric to follow as it is representative of accounts which trialed the Ekso GT via the rental program, and then decided to make the capital commitment, which is significant, at around $130K per Ekso GT." (8/8/2019)

Has Ekso Bionics been receiving favorable news coverage?

News stories about EKSO stock have been trending very negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ekso Bionics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Ekso Bionics.

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,170,000 shares, an increase of 10.8% from the September 30th total of 2,860,000 shares. Based on an average daily trading volume, of 483,500 shares, the days-to-cover ratio is presently 6.6 days. Currently, 4.3% of the shares of the company are sold short. View Ekso Bionics' Current Options Chain.

Who are some of Ekso Bionics' key competitors?

What other stocks do shareholders of Ekso Bionics own?

Who are Ekso Bionics' key executives?

Ekso Bionics' management team includes the folowing people:
  • Mr. Steven A. Sherman, Exec. Chairman (Age 73)
  • Mr. Jack Peurach, Pres, CEO & Director (Age 53)
  • Mr. John F. Glenn, CFO & Sec. (Age 57)
  • Mr. William Shaw, Chief Commercial Officer (Age 45)
  • Ms. Foon Lim Chwee, Pres of APAC

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $0.62.

How big of a company is Ekso Bionics?

Ekso Bionics has a market capitalization of $46.47 million and generates $11.33 million in revenue each year. The company earns $-26,990,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe.View Additional Information About Ekso Bionics.

What is Ekso Bionics' official website?

The official website for Ekso Bionics is http://www.eksobionics.com/.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]


MarketBeat Community Rating for Ekso Bionics (NASDAQ EKSO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel